One-Liner
A consumer tool that tells patients whether their insurance plan covers the new oral GLP-1 obesity medications and what prior-authorization criteria their doctor must cite to get approval.
AI Thinking Process
Thread 8: Lilly Foundayo oral GLP-1 approved 2026-04-01. Enter insurance plan + employer, get formulary coverage status + prior-auth pathway details. $29 report fee or pharmacy affiliate commission.
Consumer one-shot advisory unit economics (CAC>LTV in free-comparison-tool verticals) + competitor check (GoodRx, CoverMyMeds, RxSaver, Hazel Health all exist). Double kill. Space is hyper-competitive.
Kill Reason
GoodRx, Cost Plus Drugs, RxSaver, CoverMyMeds, and multiple funded startups already occupy this space. GLP-1 specific navigation is a feature any of them ships in a sprint. Additionally, consumer one-shot advisory tools priced at $29-49 structurally fail unit economics when customer acquisition cost exceeds lifetime value in verticals where free comparison tools already exist.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.